Consortium Building
Lead Research Organisation:
Imperial College London
Department Name: Dept of Medicine
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
- Imperial College London (Lead Research Organisation)
- General Electric (Collaboration)
- Neuro RX Research (Collaboration)
- Novartis (Collaboration)
- MULTIPLE SCLEROSIS SOCIETY (Collaboration)
- Bristol-Myers Squibb (Collaboration)
- Sanofi (Collaboration)
- MULTIPLE SCLEROSIS TRUST (Collaboration)
- Roche Pharmaceuticals (Collaboration)
- Biogen Idec (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- MERCK (Collaboration)
People |
ORCID iD |
| Paul Matthews (Principal Investigator) |
Publications
Battaglini M
(2014)
Automated identification of brain new lesions in multiple sclerosis using subtraction images.
in Journal of magnetic resonance imaging : JMRI
Calsolaro V
(2021)
Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load.
in Molecular psychiatry
Datta G
(2017)
Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
in Brain : a journal of neurology
Datta G
(2017)
11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis.
in Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Evangelou E
(2021)
Alcohol consumption in the general population is associated with structural changes in multiple organ systems.
in eLife
Faergeman SL
(2020)
A novel neurodegenerative spectrum disorder in patients with MLKL deficiency.
in Cell death & disease
Gafson A
(2017)
Personalised medicine for multiple sclerosis care.
in Multiple sclerosis (Houndmills, Basingstoke, England)
| Description | Working Party on Genomics, Health Records, Database Linkage and Privacy, Nuffield Council on Bioethics |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Biogen OPTIMISE |
| Amount | £5,200,000 (GBP) |
| Organisation | Biogen Idec |
| Sector | Private |
| Country | United States |
| Start | 07/2018 |
| End | 06/2025 |
| Description | Celgene Funding for the OPTIMISE Consortium |
| Amount | £1,700,000 (GBP) |
| Organisation | Bristol-Myers Squibb |
| Department | Celgene |
| Sector | Private |
| Country | United States |
| Start | 10/2019 |
| End | 09/2026 |
| Description | Investigator led Collaborative Grant |
| Amount | £725,000 (GBP) |
| Organisation | Biogen Idec |
| Sector | Private |
| Country | United States |
| Start | 10/2014 |
| End | 10/2017 |
| Description | MS Society Project grant |
| Amount | £175,000 (GBP) |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2003 |
| End | 03/2006 |
| Description | Merck funding for OPTIMISE |
| Amount | £450,000 (GBP) |
| Organisation | Merck |
| Sector | Private |
| Country | Germany |
| Start | 01/2020 |
| End | 12/2023 |
| Description | OPTIMISE |
| Amount | € 725,000 (EUR) |
| Organisation | Biogen |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 08/2017 |
| Description | Pilot Grant |
| Amount | € 74,995 (EUR) |
| Organisation | International Progressive MS Alliance |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2014 |
| End | 07/2015 |
| Description | Pilot Grant |
| Amount | £75,000 (GBP) |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 06/2016 |
| Description | Progressive MS Alliance Innovation Awards |
| Amount | € 75,000 (EUR) |
| Organisation | National Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 08/2014 |
| End | 07/2015 |
| Description | GE Healthcare |
| Organisation | General Electric |
| Department | Neurosciences; GE Healthcare |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | MRI-PET research and development, led DPUK MRI-PET Network organisation, obtaining funding, maintaining collaborations |
| Collaborator Contribution | Provision of instrument, support for optimisation, research funding and support |
| Impact | Support for DPUK equipment infrastructure award |
| Start Year | 2016 |
| Description | GSK |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Creation of a public-private consortium for stratified medicine and support for PET research |
| Collaborator Contribution | Leadership, direction of joint research agenda, support for science activity planning |
| Impact | Grant application and support for research imaging |
| Start Year | 2011 |
| Description | MS Society of Great Britain and Northern Ireland |
| Organisation | Multiple Sclerosis Society |
| Department | Neurosciences |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Creation of a public-private consortium for stratified medicine |
| Collaborator Contribution | Leadership, direction of joint research agenda, support for science activity planning |
| Impact | Grant application |
| Start Year | 2012 |
| Description | MS Trust |
| Organisation | Multiple Sclerosis Trust |
| Department | Neurosciences |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Creation of a public-private consortium for stratified medicine |
| Collaborator Contribution | Leadership, direction of joint research agenda, support for science activity planning |
| Impact | Grant application |
| Start Year | 2011 |
| Description | NeuroRx |
| Organisation | Neuro RX Research |
| Department | Neurosciences |
| Country | Canada |
| Sector | Private |
| PI Contribution | Creation of a public-private consortium for stratified medicine |
| Collaborator Contribution | Leadership, direction of joint research agenda, support for science activity planning |
| Impact | Grant application |
| Start Year | 2011 |
| Description | Novartis |
| Organisation | Novartis |
| Department | Neurosciences |
| Country | United States |
| Sector | Private |
| PI Contribution | Development of continuing professional education for clinicians in MS pathology and therapeutics |
| Collaborator Contribution | Funding, organisational support |
| Impact | Publication - Practical Neurology and one under submission |
| Start Year | 2014 |
| Description | OPTIMISE Pharmacovigilance Study |
| Organisation | Biogen Idec |
| Country | United States |
| Sector | Private |
| PI Contribution | Developed collaborative concept and technology, led management and implementation |
| Collaborator Contribution | Input regarding design, support for implementation and funding |
| Impact | None as yet |
| Start Year | 2017 |
| Description | OPTIMISE Pharmacovigilance Study |
| Organisation | Bristol-Myers Squibb |
| Department | Celgene |
| Country | United States |
| Sector | Private |
| PI Contribution | Developed collaborative concept and technology, led management and implementation |
| Collaborator Contribution | Input regarding design, support for implementation and funding |
| Impact | None as yet |
| Start Year | 2017 |
| Description | OPTIMISE Pharmacovigilance Study |
| Organisation | Merck |
| Department | Merck UK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developed collaborative concept and technology, led management and implementation |
| Collaborator Contribution | Input regarding design, support for implementation and funding |
| Impact | None as yet |
| Start Year | 2017 |
| Description | Roche |
| Organisation | Roche Pharmaceuticals |
| Country | Global |
| Sector | Private |
| PI Contribution | Creation of a public-private consortium for stratified medicine |
| Collaborator Contribution | Leadership, direction of joint research agenda, support for science activity planning |
| Impact | Grant application |
| Start Year | 2011 |
| Description | Sanofi |
| Organisation | Sanofi |
| Department | Genzyme Corporation |
| Country | United States |
| Sector | Private |
| PI Contribution | Creation of a public-private consortium for stratified medicine |
| Collaborator Contribution | Leadership, direction of joint research agenda, support for science activity planning |
| Impact | Grant application |
| Start Year | 2011 |
| Description | Head of Div coordination of open day for patients and charities |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Divisional open day attended by about 100 patients, carers, and charity Follow up article in Daily Telegraph on line |
| Year(s) Of Engagement Activity | 2012 |
| Description | One Mind for Research Annual Meeting, USA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | One Mind for Research Annual Meeting, Johns Hopkins University, Baltimore, Maryland, May 2013 - OPTIMISE: a programme for stratified medicine in MS Generating new public-private funding for brain research |
| Year(s) Of Engagement Activity | 2013 |